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Objectives The purpose of this study was to investigate the role of ivabradine in the treatment of symptomatic inappropri-
ate sinus tachycardia using a double-blind, placebo-controlled, crossover design.
Background Due to its If blocking properties, ivabradine can selectively attenuate the high discharge rate from sinus node
cells, causing inappropriate sinus tachycardia.
Methods Twenty-one patients were randomized to receive placebo (n  10) or ivabradine 5 mg twice daily (n  11) for
6 weeks. After a washout period, patients crossed over for an additional 6 weeks. Each patient underwent symp-
tom evaluation and heart rate assessment at the start and finish of each phase.
Results After taking ivabradine, patients reported elimination of 70% of symptoms (relative risk: 0.25; 95% CI: 0.18 to
0.34; p  0.001), with 47% of them experiencing complete elimination. These effects were associated with a
significant reduction of heart rate at rest (from 88  11 beats/min to 76  11 beats/min, p  0.011), on
standing (from 108  12 beats/min to 92  11 beats/min, p  0.0001), during 24 h (from 88  5 beats/min
to 77  9 beats/min, p  0.001), and during effort (from 176  17 beats/min to 158  16 beats/min,
p  0.001). Ivabradine administration was also associated with a significant increase in exercise performance.
No cardiovascular side effects were observed in any patients while taking ivabradine.
Conclusions In this cohort, ivabradine significantly improved symptoms associated with inappropriate sinus tachycardia and
completely eliminated them in approximately half of the patients. These findings suggest that ivabradine may
be an important agent for improving symptoms in patients with inappropriate sinus tachycardia. (J Am Coll
Cardiol 2012;60:1323–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.031Inappropriate sinus tachycardia (IST) is a clinical syndrome
characterized by nonparoxysmal palpitations at rest and/or
early during exercise associated with a relative or absolute
increase in sinus rate out of proportion to physiological need
(1–4). The clinical manifestations of this syndrome are
diverse and variable. Patients are mainly young women, and
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accepted June 26, 2012.clinical symptoms range from intermittent palpitations to
multisystem symptoms including light-headedness, pre-
syncope, syncope, orthostatic intolerance, chest pain or
pressure, headache, myalgia, dyspnea, fatigue, abdominal
discomfort, anxiety, and depression (5). On 12-lead electro-
cardiography (ECG), the P-wave morphology during tachy-
cardia is nearly identical to that in sinus rhythm. Although the
mean 24-h or daytime heart rate (HR) exceeding 95 beats/min
or sinus rate increase from a supine/semiorthostatic to a
See page 1330
standing position 25 to 30 beats/min provides some quanti-
fiable parameters for IST, the diagnosis may be elusive. In fact,
symptoms can be different from palpitations and may repro-
ducibly occur with HRs lower than those conventionally
1324 Cappato et al. JACC Vol. 60, No. 15, 2012
Ivabradine in Inappropriate Sinus Tachycardia October 9, 2012:1323–9accepted. In addition, reproduc-
ibility and correlation of symp-
toms, activity, and HR can be
elusive in a single patient (6).
The pathophysiology of IST is
poorly understood, although
mechanisms such as excessive
sympathetic influences, reduced
parasympathetic influences, ex-
cessive intrinsic HR, ectopic activity of the sinus node, and
-receptor antibodies have been proposed as substrates for
this arrhythmia (1,4,7). In patients in whom neural imbal-
ance is suspected, the integrity of the baroreceptor reflex
response appears to focus on impairment of efferent stimu-
lation rather than on alterations of the neural reflex mech-
anisms as a possible cause of IST (4). The extent to which
each of these and other possible mechanisms contribute to
tachycardia and associated symptoms is unknown.
Regardless of the primary mechanism, a common de-
nominator potentially involved in an accelerated sinus rate is
higher-than-normal activation during diastole of the “pace-
maker” If current, the ionic current known to generate the
spontaneous diastolic depolarization of the sinoatrial node
(8). A class of drugs investigated in patients with IST is
represented by -adrenergic antagonists. Although effec-
tive, their main limitation is the wide range of actions on the
cardiovascular and other systems, which both complicate
interpretation of the effects of HR lowering and often cause
intolerable side effects (9).
The recent introduction of ivabradine (10,11), a specific If
blocker with no interactions with the cardiovascular system,
has provided investigators with the unique opportunity to
test the impact of pure If blockade on cardiac chronotropy
and the variable symptoms associated with this syndrome.
Preliminary reports suggest that ivabradine may be effective
in patients with this arrhythmia (12–15). Using a prospec-
tive, randomized, placebo-controlled, crossover design, we
investigated the role of ivabradine in the treatment of
patients with IST.
Methods
Study design. This study is a randomized, double-blind,
placebo-controlled, crossover trial of oral ivabradine con-
ducted in patients with IST. After a baseline screening
assessment, patients were randomized to start with a 6-week
course of either placebo or ivabradine according to a
double-blind model (phase 1, Fig. 1). Randomization was
performed on the basis of computer-generated random
numbering. Next, after a washout period of 7 days at the end
of which HRs and exercise performance were reassessed,
patients switched treatment for an additional 6 weeks (phase
2), with each patient acting as his or her own control. All
enrolled patients underwent 12-lead ECG in the supine and
standing positions, 24-h Holter monitoring, and exercise
Abbreviations
and Acronyms
ECG  electrocardiography
HR  heart rate
IST  inappropriate sinus
tachycardia
RR  relative risk12-lead ECG at baseline and at the end of each phase for atotal of 3 assessments. Placebo pills were identical in
appearance to ivabradine pills and were taken according to
the same schedule (2 times per day). Three doses of
delivered drug were available for both arms of this study: a
low dose, a high dose, and an intermediate dose. Such doses
corresponded to ivabradine 2.5 mg, 7.5 mg, and 5 mg,
respectively. Group A comprised patients first assigned to
placebo and then switched to ivabradine, whereas group B
comprised patients first assigned to ivabradine and then
switched to placebo. Regardless of randomization, the
assigned drugs were taken twice daily at the initial interme-
diate dose and downgraded to the low dose in case of
intolerable side effects or upgraded to the high dose if well
tolerated at 3 weeks from onset of each crossover phase. All
patients were informed about the investigational nature of
the study and gave their written informed consent. The
study protocol was approved by the ethics committee and
the institutional committee on human research of our
hospital.
Inclusion/exclusion criteria. Entry criteria included a
symptomatic mean resting HR 95 beats/min during the
daytime hours of 24-h Holter monitoring and/or a rapid
stable symptomatic increase in resting HR 25 beats/min
when moving from a supine to a standing position or in
Figure 1 Flowchart of Study Protocol
After enrollment, washout and baseline assessments were performed before
randomization. Patients were kept in the assigned treatment arm for 6 weeks
and subsequently crossedover to the alternate treatment arm after a washout
period. ECG  electrocardiography.
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the presence of underlying heart disease, a history of
paroxysmal supraventricular tachycardia, history of sick
sinus syndrome, diagnosis of orthostatic hypotension, con-
ditions causing compensatory sinus tachycardia (anemia,
hyperthyroidism, infections, hypovolemia, pheochromocy-
toma, diabetes mellitus, or drug abuse), receiving antiar-
rhythmic therapy, renal or hepatic insufficiency, and receiv-
ing potent inhibitors of P450 3A4. Structural heart disease
was excluded in all patients by means of transthoracic
echocardiography (Vivid 7 Dimension, GE Healthcare,
Inc., London, United Kingdom).
Adverse effects and compliance. Adverse effects were
collected by patient report and periodic interviews with
dedicated research personnel. To ensure medication com-
pliance, a pill count was performed at the end of each study
period. The minimum compliance rate for inclusion in the
study period of the analysis was 80%. No patients were
excluded from the analysis because of noncompliance.
Sample size calculation. The primary efficacy outcome
was resolution of symptoms associated with assignment to
ivabradine. We pre-specified a clinically relevant minimum
detectable degree of ivabradine-related overall symptom
elimination of 70% within a pool of 7 symptom indicators
(palpitations, pre-syncope/syncope, orthostatic intolerance,
chest pain, dyspnea, and anxiety) associated with IST. To
this aim, investigators were required to complete a patient
symptom form at baseline, after phase 1, and after phase 2
during a scheduled patient interview. Each of the 7 symp-
tom indicators was scrutinized and filed according to a yes
or no dichotomy criterion. Therefore, we identified a sample
size in each treatment sequence (placebo ¡ ivabradine and
ivabradine ¡ placebo) of 8 for an overall sample size to have
80% power to detect the pre-specified minimum difference
at a 2-sided significance level of 0.05. Sample size calcula-
tion was performed by Proc Power of the SAS statistical
software package version 9.2 (SAS Institute, Cary, North
Carolina).
Summary Statistics for HR Measurements, Speed During Exercise,D ring Exercise at Different Treatment PhaseTable 1 Summary Statistics for HR Measur ments, Spe d DuriDuring Exercise at Different Treatment Phase
Variable Baseline Place
HR on standing 107.7 11.5 109.0
HR at rest 88.5 11.2 87.1
HR change between rest and standing 19.3 8.8 22.0
24-h HM mean HR 88.8 5.3 88.9
24-h HM rather during the daytime 98.4 11.2 98.6
24-h HM HR during the nighttime 77.3 8.0 75.6
24-h HM maximum HR 153.8 23.9 145.9
24-h HM minimum HR 58.9 7.8 59.1
HR during maximum exercise 177.5 16.6 170.7
Speed during exercise, km/h 5.9 1.1 6.1
Exercise duration, min 7.2 2.5 7.6
METs during exercise 10.1 2.6 10.2Values are mean  SD. Placebo and ivabradine p values calculated with the Wilcoxon test. *Paired com
HM  Holter monitoring; HR  heart rate.Statistical analysis. Baseline and demographic character-
istics were summarized by the use of mean  SD for
continuous variables and percentage for categorical vari-
ables. The influence of tested therapies on symptoms
associated with IST was evaluated using a conditional
mixed-effects logistic interpolation model. Relative risk
reduction and 95% confidence intervals were reported across
treatment phases, and the overall mixed-effects interpola-
tion was performed.
The power analysis of HR was performed by simulation
considering an HR reduction (effect size) of 10 to 15
beats/min, group variability (SD) of 10 to 15 beats/min,
and a correlation coefficient between post- and pre-
treatment values ranging from 0.3 to 0.5 to detect the
pre-specified minimum difference at a 2-sided significance
level of 0.05.
Continuous variables were investigated by means of a
mixed-effects generalized linear model having secondary
continuous outcomes as response to variable and treatment-
phase interaction as covariate. Paired differences between
post-placebo and post-ivabradine status were investigated
by Wilcoxon signed rank test or t test according to variable
kewness. Analysis results are reported in Table 1.
All statistical evaluations were performed using SAS
tatistical software package version 9.2 (SAS Institute), the
lpha value of 0.05 was considered statistically significant,
nd all tests were 2-tailed.
esults
emographics and baseline data. Of 29 eligible patients
dentified by the study team, 21 met the entry criteria and
ere enrolled in the study after providing written informed
onsent. Of them, 2 could not complete the follow-up due
o side effects experienced during treatment with ivabradine
n 1 patient (phosphenes) and placebo in the other patient
dizziness and nausea). Overall, 19 patients completed the
ollow-up. Of them, 10 were first assigned to ivabradine and
cise Duration, and METsercise, Exercise Duration, and METs
Ivabradine p Value* R2 p Value†
91.6 10.7 0.0001 0.35 0.0004
76.1 10.5 0.0117 0.28 0.004
15.5 9.9 0.0249* 0.13 0.2029
77.0 8.8 0.0010 0.37 0.0002
84.7 9.0 0.0001 0.39 0.0001
65.6 7.1 0.0001* 0.35 0.0004
137.5 26.8 0.0011 0.09 0.4200
51.4 11.6 0.0178* 0.24 0.0132
158.1 16.3 0.0013 0.24 0.0128
6.6 1.7 0.0006* 0.03 0.8855
8.9 2.8 0.0156 0.05 0.7093
11.1 3.0 0.0005 0.03 0.9173Exerng Ex
bo
12.9
13.0
10.2
8.3
11.1
9.1
25.1
12.8
15.7
1.3
2.8
3.0parison results; †mixed-effect generalized linear model analysis results.
T
2
d
c
r
1326 Cappato et al. JACC Vol. 60, No. 15, 2012
Ivabradine in Inappropriate Sinus Tachycardia October 9, 2012:1323–99 to placebo. Table 2 summarizes the demographic and
clinical characteristics of the study population. Seventeen
patients were female with a mean age of 37.1  12.7 years.
hree patients presented with 1 or more symptoms at rest,
had symptoms only during effort, and 14 had symptoms
uring both conditions. Symptoms were predominantly
haracterized by palpitations, but other symptoms were
eported either alone or in association with palpitations.
The mean HR at enrollment was 88.5  11.2 beats/min
in the supine position and 107.7  11.5 beats/min in the
orthostatic position, with a mean change of 19.3  8.8
beats/min. During 24-h Holter monitoring, the mean,
minimum, and maximum HR were 88.8  5.3 beats/min,
58.9  7.8 beats/min, and 153.8  23.9 beats/min, respec-
tively. During the daytime, the mean HR was 98.4  11.2
beats/min, whereas during the nighttime, it was 77.3  8.0
beats/min. The maximal HRs assessed during stress ECG
were 177.5 16.6 beats/min with a mean change of 69.5
Demographic and Clinical Characteristicsof the 19 Patients Completing Follow-UpTable 2 D mographic and Clinical Characteristicsof the 19 Patients Completing Follow-Up
Age, yrs 37.1 12.7
Female 17
Symptoms
Palpitations
At rest 3
During exercise 2
At rest and during exercise 14
Pre-syncope/syncope 1
Intolerance on standing 6
Chest pain 4
Dyspnea
At rest 1
During exercise 7
At rest and during exercise 1
Fatigue
At rest 3
During exercise 9
At rest and during exercise 1
Anxiety 2
Risk factors for cardiomyopathy
Smoking 4
Hypertension 0
Hypercholesterolemia 2
Diabetes 0
Previous therapy
No. of patients with previously taking beta-blockers 14
No. of patients with previous nondihydropyridine calcium
antagonists
4
Echocardiographic data
Left ventricular end-diastolic diameter, mm 43.6 3.6
Left ventricular ejection fraction 0.64 7.7
Septal wall thickness, mm 8.6 1.2
Posterior wall thickness, mm 9.0 1.1
Left atrium maximum anteroposterior diameter, mm 32.8 3.3
Values are mean  SD or n.12.3 beats/min relative to baseline standing HR. During a7.2  2.5-min exercise duration, patients expended 10.1 
2.6 METs at a speed of 5.9  1.1 km/h.
Effects of ivabradine on symptoms and HR. After the
initial dose of 5.0 mg twice daily, ivabradine was increased
to 7.5 mg twice daily in 11 patients according to the
protocol and was decreased to 2.5 mg twice daily in 2
patients because of weakness or dizziness. Similarly, in the
placebo arm, an increase to the maximum dose was possible
in 10 patients, whereas a decrease to the minimal dose was
required in 2 patients because of patient discomfort such as
nausea and weakness. Elimination of 70% of symptoms at
baseline was observed in 14 patients (67%) in response to
ivabradine, with 9 patients experiencing complete elimina-
tion. Another 5 patients (24%) reported elimination of 50%
of symptoms at baseline in response to ivabradine. The
remaining 2 patients reported elimination of 33% of symp-
toms at baseline in response to ivabradine. Figure 2 shows
the fiducial point and the 95% confidence interval of the
relative risk (RR) estimate of symptom evaluation when
comparing placebo and ivabradine in the overall population
(overall effect). Also shown are the fiducial points and the
RR estimate of subgroup comparisons obtained within
group A patients, within group B patients, between patients
assigned to groups A and B during study phase 1 (group A
vs. B), and between patients assigned to groups A and B
during study phase 2 (group B vs. A). Overall, 70% of
baseline symptoms were abolished after ivabradine admin-
istration compared with placebo (RR: 0.25; 95% confidence
interval, 0.18 to 0.34; p  0.001). This difference was
confirmed when comparing ivabradine and placebo within
each combination of subgroup RR estimate analysis (p 
0.001 for all comparisons). Nine patients (4 in group A and
5 in group B) reported elimination of all symptoms within
few days after starting on ivabradine. Table 3 is a summary
of a symptom evaluation report as collected at baseline and
after completion of the 6-week periods of placebo and
ivabradine. Complete elimination of symptoms in 9 patients
during ivabradine therapy was not associated with signifi-
cantly greater degrees of HR reduction compared with
patients with incomplete elimination of symptoms. Among
the 10 patients first randomized to ivabradine, 9 (90%)
experienced recurrence or an increase in symptoms when
crossed over to placebo. Among the 11 patients first
randomized to placebo, all (100%) experienced improve-
ment or elimination of symptoms when crossed over to
ivabradine.
Summary statistics of HR measurement and exercise
capacity are reported in Table 1 and Figure 3. Compared
with placebo, ivabradine significantly decreased baseline
supine (76.1 10.5 beats/min; p vs. baseline 0.0117) and
orthostatic HR (91.6 10.7 beats/min; p 0.0001) as well
as HR change (15.5  9.9 beats/min; p  0.0249).
Similarly, the mean (77.0  8.8 beats/min; p  0.001),
minimum (51.4  11.6 beats/min; p  0.0178), and
maximum (137.5  26.8 beats/min; p  0.0011) HRs were
also significantly reduced. HR also decreased during the
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during the nighttime (65.6  7.1 beats/min; p  0.0001).
Finally, ivabradine reduced maximum HR during stress
ECG (158.1  16.3 beats/min; p  0.0013). Changes in
aximum HR were associated with longer exercise duration
8.9  2.8 min; p  0.0156), larger expenditure capabilities
11.1  3.0 METs; p  0.0005) at higher speed (6.6  1.7
km/h). All possible combinations but 1 of data comparison
between placebo and ivabradine groups had a power calcu-
lation 0.8.
Discussion
This study is the first randomized, double-blind, placebo-
controlled, crossover trial to evaluate the impact of ivabra-
dine on symptoms and HR at various conditions in patients
with IST. The crossover design allowed each subject to
serve as his or her own internal control, thereby reducing the
possibility of confounding, given the variable symptoms and
their uncertain association with HR changes induced by
Figure 2 Comparative Assessment of Symptoms in Patients W
Receiving Placebo Versus Patients Receiving Ivabrad
Comparisons include overall effect, effects within group A (receiving placebo first),
group A and effects when comparing group A and group B. CI  confidence interva
Symptom Evaluation as ReportedDuring Patient Interview at Baseline and6 Weeks After Placebo and Iv bradine A ministration
Table 3
Sympt m Evaluation s Reported
During Patient Interview at Baseline and
6 Weeks After Placebo and Ivabradine Administration
Symptom Baseline Placebo Ivabradine
Overall 65 60 19
Palpitations 17 15 7
Pre-syncope/syncope 1 0 0
Orthostatic intolerance 6 6 1
Chest pain 4 1 1
Dyspnea 9 8 2
Fatigue 13 12 3
Anxiety 2 4 2pValues are n.ivabradine. We found that ivabradine eliminated 70% of
symptoms reported at baseline with 50% of patients
reporting elimination of all symptoms. These effects were
associated with a significant reduction of HR at baseline,
after standing, during 24 h, during the daytime, during the
nighttime, and at maximum stress test.
The benefit of ivabradine to reduce HR is well docu-
mented. In patients with chronic heart failure, treatment with
ivabradine has been associated with reduced adverse clinical
outcomes directly correlated with the drug-dependent degree
of HR reduction (15,16). In patients with stable coronary
artery disease, ivabradine-dependent HR reduction may result
in a reduction of adverse clinical outcomes in subgroups with a
baseline HR of70 beats/min (17). Recent data suggest that
ivabradine may also be effective in patients with IST. The
specific mechanism of action is likely to be related to the
ivabradine-mediated If attenuation, ultimately resulting in
R reduction. However, most such studies are case reports
r uncontrolled studies. In one study, Schulze et al. (12)
eported the case of a young female patient affected by IST
n whom sustained success was achieved by administering
0 mg/day of oral ivabradine. In another study, Calò et al.
18) reported the efficacy of ivabradine administration in 16
onsecutive patients. Data from this study suggest that
vabradine significantly reduces the mean and maximum
4-h HR and that the impact of ivabradine on HR
eduction tends to improve over time, as suggested by the
reater degree of change observed at 6 months compared
ith that observed at 3 months. Unfortunately, no data on
he impact of HR reduction on symptoms were available in
his cohort.
ignificance. In this study, ivabradine-mediated effects on
appropriate Sinus Tachycardia
s within group B (receiving ivabradine first), effects when comparing group B and
 relative risk.ith In
ine
effect
l; RRatient symptoms were a significant reduction of HR in
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determinant of symptom manifestation in these patients.
Notably, in some patients, symptoms were not reduced or
eliminated despite similar degrees of ivabradine-mediated
HR reduction. This latter observation suggests that in-
creased HR may not be the only determinant of symptoms
or that patients with similar HRs may experience different
degrees of symptoms or present with variable symptom
threshold. Based on previous data (18), it is possible that
ivabradine administration for 6 weeks considered in our
study would be associated with a further reduction of HR
and a possible additional beneficial effect on symptoms,
although this observation is only speculative and will require
further assessment.
The uniform ability of ivabradine to reduce HR in patients
with IST is a result of its specific mechanism of action. In fact,
the ivabradine-dependent reduction in the slope of slow
diastolic depolarization (19) produces a reduced rate of firing
Figure 3 Histograms of Heart Rates
At baseline, during placebo, and during ivabradine administration as assessed on
during 24-h Holter monitoring (mean, daytime mean, nighttime mean, maximum, aregardless of the mechanisms, whether intrinsic or autonomi-cally mediated, ultimately causing IST. This may justify the
potential efficacy of ivabradine in a significant proportion of
patients with this arrhythmia regardless of the underlying
mechanism in each single case. Drug-related reduced HR and
increased cardiac output may result in a reduction of symptoms
and better exercise tolerance in these patients.
The incidence of ivabradine-related side effects does not
appear to be as relevant as in trials of patients with
congestive heart failure or coronary artery disease, thus
making administration of this drug rather comfortable. It is
possible that this finding is associated with the younger age
and lower incidence of comorbidities in patients with IST
compared with patients with heart failure or coronary artery
disease. The lack of general cardiovascular effects makes
administration of ivabradine the preferred choice compared
with beta-blocking agents for the treatment of IST. Ivabra-
dine appears to be the preferred choice also compared with
catheter modulation of the sinus node because this tech-
ing, at rest (including heart rate change between the 2 conditions),
imum), and at maximum exercise.stand
nd minnique has not proved to be very effective and may be
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It is possible that mechanisms other than increased expres-
sion of the If current are responsible for IST in the group of
nonresponders to ivabradine in our study. Among such
mechanisms, aberrations in the calcium clock may also be
considered (21).
Study limitations. Although we had sufficient power to
detect significant differences in symptom reduction, the
sample size did not allow us to differentiate between drug
responders and nonresponders and identify possible predic-
tors of response. Given the relatively short follow-up,
efficacy and safety of oral ivabradine could not be tested
according to a long-term treatment schedule. Based on
previous studies, ivabradine efficacy tends to increase further
from 3 to 6 months follow-up in patients with IST (18).
However, there are no data on the long-term safety of the
drug, and further studies with longer follow-up are required
to address this issue. Based on these observations, larger
randomized trials designed to evaluate long-term safety and
efficacy and to detect responders versus nonresponders
should be performed before routine adoption of ivabradine
for the treatment of IST.
Conclusions
The present study shows that after 4 weeks of oral admin-
istration, ivabradine eliminates 70% of the variable symp-
toms associated with IST and that complete elimination of
symptoms can be expected in50% of cases. The long-term
efficacy and safety profile of ivabradine for the therapy of
this arrhythmia is worthy of further investigation.
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